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Objective
Personalized dynamic monitoring system development
of a patient with cardiovascular disease on the basis of
large-scale physical, genomic, proteomics, metabolomics,
and immunological studies.
Technical approaches
1. Remote real-time functional monitoring of patients;
2. Genome profiling (NGS);
3. Proteome profiling (IEF, LC MS/MS);
4. Cell function research (Flow cytometry, Live cell
imaging);
5. Drugs and metabolites concentration control and
association it with genomic constitution (LC MS/MS);
6. Quantification plasma concentration of the drugs
and their metabolites, enzymes (LC MS/MS);
7. Immunologic profiling (ELISA, flow cytometry).
Results
We examined patients –non-responding on pharma-
cotherapy. All patients had “wild genotype” of the isoen-
zymes of the cytochrome P450 [1]. Drug plasma level
decreased in presence high activity of the vessel
endothelium growth factor and interleukin – 8. NADPH
–reductase activity has decreased also. These results are
showing activity of inflammatory processes and progres-
sive of the diseases [2]. However, expression gene of the
p-glycoprotein is increased; PEPT transport activity is
increased too. Genomics and proteomic monitoring is
necessary in this case.
The effectiveness of drug treatment depends on the
patient’s genetic constitution. One of the general net-
works is the drugs utilization system, including proteins
of transport and biotransformation system. Identification
of polymorphisms in genes encoding proteins of these
systems, as well as polymorphisms in genes of responsi-
ble for inflammatory and oxidative processes, provide a
full-scale monitoring of the majority of the factors
responsible for the effectiveness of drug therapy. In this
case, monitoring of genetic factors in the personalized
approach coupled with the assessment of immune sys-
tem cells functioning, and general functional monitoring
of patients (ECG, blood pressure), and a daily quantifi-
cation relevant metabolites. The data based on the phy-
siological parameters, the functional status of the
immune system, genetic polymorphisms, and local pro-
tein profiles are compared with data on the pharmacoki-
netics compared with different therapeutic protocols.
The result revealed fundamental laws of individual pro-
cesses at different levels that take place in the treatment
of cardiovascular disorders.
Outlook for experts
Obtained data focused on the basic monitoring protocol
development and identification of the new biomarkers.
It is the first case of high throughout testing of different
treatment protocols. Their comparison leads to
* Correspondence: svetlana_babak@yahoo.com
1Laboratory of Clinical Pharmacology, Immanuel Kant Baltic Federal
University, 14, Nevskogo, Kaliningrad, 236041, Russia
Full list of author information is available at the end of the article
Babak et al. EPMA Journal 2014, 5(Suppl 1):A80
http://www.epmajournal.com/content/5/S1/A80
© 2014 Babak et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
developing of new treatment approaches based on indi-
vidual molecular, cell and physiological parameters.
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